Canopy Growth Corporation - Common Shares (CGC)

NEW YORK, April 12, 2025 (GLOBE NEWSWIRE) --

NEW YORK, April 12, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Canopy Growth Corporation (“Canopy” or the “Company”) (NASDAQ: CGC) and certain officers.  The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-01877, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Canopy securities between May 30, 2024 and February 6, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Canopy Growth Corporation (“Canopy” or the “Company”) (NASDAQ: CGC) securities between May 30, 2024 and February 6, 2025, inclusive (the “Class Period”). Canopy investors have until June 3, 2025 to file a lead plaintiff motion.

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Canopy Growth Corporation (“Canopy Growth” or the “Company”) (NASDAQ:CGC) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired Canopy Growth securities between May 30, 2024 and February 6, 2025, both dates inclusive (the “Class Period”). Investors have until June 3, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Canopy Growth Corporation (“Canopy” or the “Company”) (NASDAQ: CGC) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of Canopy Growth Corporation (“Canopy” or the “Company”) (NASDAQ: CGC) investors concerning the Company’s possible violations of federal securities laws.

NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) --

The Law Offices of Frank R. Cruz announces an investigation of Canopy Growth Corporation (“Canopy” or the “Company”) (NASDAQ: CGC) on behalf of investors concerning the Company’s possible violations of federal securities laws.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Canopy Growth Corporation (“Canopy Growth” or “the Company”) (NASDAQ: CGC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Canopy Growth Corporation (NASDAQ: CGC) securities between May 30, 2024 and February 6, 2025. Canopy, together with its subsidiaries, produces, distributes, and sells cannabis and hemp-based products for recreational and medical purposes.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Canopy Growth Corporation (NASDAQ: CGC) between May 30, 2024 and February 6, 2025. Canopy Growth describes itself as a company that “produces, distributes, and sells cannabis and hemp-based products for recreational and medical purposes.”

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has launched Spectrum Reserve, a new premium medical cannabis brand in Canada. Designed to meet the evolving needs of medical cannabis patients, Spectrum Reserve represents the peak of cannabis cultivation – featuring flower selected for size, potency, and terpene levels through rigorous in-house standards during cultivation and post-harvest.

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that it has made an optional early prepayment under its senior secured term loan (the “Term Loan”) in an aggregate principal amount equal to US$100 million at a discounted price of US$97.5 million. This results in interest expense savings of approximately US$13 million on an annualized basis.

Walking into Vibe Cultivators, an indoor marijuana farm in Sacramento, California, the first thing you notice is the strong, unmistakable smell of marijuana. The facility is filled with rows of plants stacked on two levels, bathed in artificial light.

Walking into Vibe Cultivators, an indoor marijuana farm in Sacramento, California, the first thing you notice is the strong, unmistakable smell of marijuana. The facility is filled with rows of plants stacked on two levels, bathed in artificial light.

The Idaho State Senate has approved a proposed constitutional amendment that would give the legislature sole authority to legalize cannabis and other drugs. The measure, known as House Joint Memorial 4, will be put to a vote in the November 2026 elections.

The Idaho State Senate has approved a proposed constitutional amendment that would give the legislature sole authority to legalize cannabis and other drugs. The measure, known as House Joint Memorial 4, will be put to a vote in the November 2026 elections.

Washington State lawmakers have once again abandoned an effort to legalize personal cannabis cultivation at home, choosing instead to maintain its felony classification. The proposed legislation, HB 1449, introduced by Representative Shelley Kloba, failed to advance past the House Appropriations Committee before the legislative deadline, effectively halting progress on the measure for this session.

Washington State lawmakers have once again abandoned an effort to legalize personal cannabis cultivation at home, choosing instead to maintain its felony classification. The proposed legislation, HB 1449, introduced by Representative Shelley Kloba, failed to advance past the House Appropriations Committee before the legislative deadline, effectively halting progress on the measure for this session.

The New Hampshire legislature recently approved a proposal to legalize the personal use and possession of recreational cannabis. However, the bill does not include provisions for the regulated sale of marijuana. The legislation, known as HB 75 and sponsored by Representative Kevin Verville, was passed in the House through a voice vote in Thursday’s afternoon session.

The New Hampshire legislature recently approved a proposal to legalize the personal use and possession of recreational cannabis. However, the bill does not include provisions for the regulated sale of marijuana. The legislation, known as HB 75 and sponsored by Representative Kevin Verville, was passed in the House through a voice vote in Thursday’s afternoon session.

Reports of alleged fraudulent activity in cannabis testing labs have surfaced once again in New York’s recreational market, with claims that some vape oil cartridges are being labeled with cannabinoid levels exceeding 100%. Similar accusations of labs inflating THC levels to meet client demands and possibly altering data meant to ensure consumer safety have been raised in other states as well.

The marijuana capital markets have encountered substantial hurdles in recent years. Investors who have been in the industry since 2019 have witnessed every phase of the market—from thrilling peaks to somber valleys.

Former U.S. President Joe Biden commuted the sentences of almost 2,500 inmates convicted of various non-violent drug offenses ( including marijuana ) during his last days in the Oval Office. Biden noted that with this last round of commutations, he has granted clemency to more Americans than any other president in U.S. history.

The marijuana industry experienced a sluggish pace of progress in 2024. Efforts to pass cannabis reform measures in Congress fell short, and the DEA delayed rescheduling cannabis as a recognized medicinal substance.